maybefalse/E+ via Getty Images
- Personalis (NASDAQ:PSNL) announces the issuance of two U.S. Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy.
- Shares up nearly 3% premarket.
- Both the patents are members of broader patent families that relate to Personalis’ early work relating to exome-wide analysis and the cell-free detection of disease.
- To date, Personalis has been granted 18 U.S. and foreign patents relating to advanced genomic sequencing and analysis solutions.